about
Massive release of extracellular vesicles from cancer cells after photodynamic treatment or chemotherapyCombining magnetic hyperthermia and photodynamic therapy for tumor ablation with photoresponsive magnetic liposomes.Duality of Iron Oxide Nanoparticles in Cancer Therapy: Amplification of Heating Efficiency by Magnetic Hyperthermia and Photothermal Bimodal Treatment.Cancer Cell Internalization of Gold Nanostars Impacts Their Photothermal Efficiency In Vitro and In Vivo: Toward a Plasmonic Thermal Fingerprint in Tumoral Environment.Can magneto-plasmonic nanohybrids efficiently combine photothermia with magnetic hyperthermia?Magnetic hyperthermia efficiency in the cellular environment for different nanoparticle designs.Virus-Templated Near-Amorphous Iron Oxide Nanotubes.Formation of biomineral iron oxides compounds in a Fe hyperaccumulator plant: Imperata cylindrica (L.) P. Beauv.Matrix and interaction effects on the magnetic properties of Co nanoparticles embedded in gold and vanadium.Doxorubicin Intracellular Remote Release from Biocompatible Oligo(ethylene glycol) Methyl Ether Methacrylate-Based Magnetic Nanogels Triggered by Magnetic Hyperthermia.Massive Intracellular Biodegradation of Iron Oxide Nanoparticles Evidenced Magnetically at Single-Endosome and Tissue Levels.Janus plasmonic-magnetic gold-iron oxide nanoparticles as contrast agents for multimodal imaging.Suppression of Ferromagnetic Double Exchange by Vibronic Phase SegregationDesign of magnetic molecularly imprinted polymer nanoparticles for controlled release of doxorubicin under an alternative magnetic field in athermal conditionsWater-Soluble Iron Oxide Nanocubes with High Values of Specific Absorption Rate for Cancer Cell Hyperthermia TreatmentCorrelating Magneto-Structural Properties to Hyperthermia Performance of Highly Monodisperse Iron Oxide Nanoparticles Prepared by a Seeded-Growth RouteJanus Magnetic-Plasmonic Nanoparticles for Magnetically Guided and Thermally Activated Cancer Therapy
P50
Q30823413-1037CD97-3C49-4E21-875D-80BD2A9981A3Q35563855-459F176B-0155-4EC2-8DDF-C3952F247050Q35894210-EC06E2A3-B4C2-47DF-B9CF-2E0843F55805Q35962185-D18587AC-D60C-4FEC-881A-CE6D8D8FBED3Q38607596-398FB78A-41D3-4449-A4B2-DF2C5CBABF47Q38996204-8ACF6478-2264-4991-AFAE-A7C2120685A7Q40753341-7D4FEC1F-204B-433E-B71F-611A16791515Q46279379-C1F74ADD-FAF4-4E6C-B0B8-10424C5F6E69Q46610368-3A2A22AF-47E6-455C-AFBA-4F61F5DECD15Q47966082-061C633B-F746-48FA-9537-A389C1FFE59AQ48606032-A8A02DF6-282A-4937-976F-705F56AC582DQ51837567-A1637190-C193-42DB-AC3C-35B9DC8B4AE3Q56899129-01A3801E-1507-40A5-BB11-0FC572262068Q57559254-6A41374F-8FB1-45C6-A024-45927171FC69Q57559337-9CBC4E2A-3592-4B0C-8CC8-D292B5809BCCQ57559342-5FA655FD-0BFD-4C9E-962A-5D2A5BBED01BQ89798437-23129586-2393-4A20-A6DE-44B938308491
P50
description
researcher ORCID: 0000-0002-5626-6129
@en
name
Ana Espinosa
@ast
Ana Espinosa
@en
Ana Espinosa
@es
Ana Espinosa
@nl
Ana Espinosa
@sl
type
label
Ana Espinosa
@ast
Ana Espinosa
@en
Ana Espinosa
@es
Ana Espinosa
@nl
Ana Espinosa
@sl
prefLabel
Ana Espinosa
@ast
Ana Espinosa
@en
Ana Espinosa
@es
Ana Espinosa
@nl
Ana Espinosa
@sl
P1053
G-9162-2011
P106
P1153
35835194400
P21
P31
P3829
P496
0000-0002-5626-6129